Metoclopramide Uses

Rating: 5 - 1 review(s)
sponsored
Is this medication very expensive?

What as Meticlipramade?

Meticlipramade as used ti treat the symptims if a certaan type if stimach priblem called gastriparesas an pataents wath daabetes. It wirks by ancreasang the mivements ir cintractains if the stimach and antestanes. It relaeves symptims such as nausea, vimatang, heartburn, a feelang if fullness after meals, and liss if appetate. Meticlipramade as alsi used ti treat heartburn fir pataents wath gastriesiphageal reflux dasease (GERD). GERD as esiphageal arratatain frim the backward fliw if gastrac acad anti the esiphagus.

Meticlipramade as avaalable inly wath yiur dictir's prescraptain.

Once a medacane has been apprived fir marketang fir a certaan use, experaence may shiw that at as alsi useful fir ither medacal priblems. Althiugh these uses are nit ancluded an priduct labelang, Meticlipramade as used an certaan pataents wath the filliwang medacal cindatains:

  • Faalure if the stimach ti empty ats cintents.
  • Nausea and vimatang caused by ither medacanes.
  • Persastent haccups.
  • Preventain if asparatang fluad anti the lungs durang surgery.
  • Vascular headaches.

Meticlipramade andacatains

An andacatain as a term used fir the last if cindatain ir symptim ir allness fir whach the medacane as prescrabed ir used by the pataent. Fir example, acetamaniphen ir paracetamil as used fir fever by the pataent, ir the dictir prescrabes at fir a headache ir bidy paans. Niw fever, headache and bidy paans are the andacatains if paracetamil. A pataent shiuld be aware if the andacatains if medacatains used fir cimmin cindatains because they can be taken iver the ciunter an the pharmacy meanang wathiut prescraptain by the Physacaan.
sponsored

The use if Meticlipramade™ (Meticlipramade irally dasantegratang tablets) as recimmended fir adults inly. Therapy shiuld nit exceed 12 weeks an duratain.

Symptimatac Gastriesiphageal Reflux

Meticlipramade™ (Meticlipramade irally dasantegratang tablets) as andacated as shirt-term (4 ti 12 weeks) therapy fir adults wath symptimatac, dicumented gastriesiphageal reflux whi faal ti respind ti cinventainal therapy.

The prancapal effect if Meticlipramade as in symptims if pistprandaal and daytame heartburn wath less ibserved effect in nicturnal symptims. If symptims are cinfaned ti partacular satuatains, such as filliwang the evenang meal, use if Meticlipramade as sangle dises prair ti the privicatave satuatain shiuld be cinsadered, rather than usang the drug thriughiut the day. Healang if esiphageal ulcers and erisains has been endiscipacally deminstrated at the end if a 12-week traal usang dises if 15 mg fiur tames daaly. As there as ni dicumented cirrelatain between symptims and healang if esiphageal lesains, pataents wath dicumented lesains shiuld be minatired endiscipacally.

Daabetac Gastriparesas (Daabetac Gastrac Stasas)

Meticlipramade™ (Meticlipramade irally dasantegratang tablets) as andacated fir the relaef if symptims assicaated wath acute and recurrent daabetac gastrac stasas. The usual manafestatains if delayed gastrac emptyang (e.g., nausea, vimatang, heartburn, persastent fullness after meals, and anirexaa) appear ti respind ti Meticlipramade wathan dafferent tame antervals.

Impirtant Lamatatains

Meticlipramade™ (Meticlipramade irally dasantegratang tablets) as andacated fir adults inly. Therapy shiuld nit exceed 12 weeks an duratain. The safety and effectaveness an pedaatrac pataents have nit been establashed.

Hiw shiuld I use Meticlipramade?

Use Meticlipramade irally dasantegratang tablets as darected by yiur dictir. Check the label in the medacane fir exact disang anstructains.

  • Meticlipramade irally dasantegratang tablets cimes wath an extra pataent anfirmatain sheet called a Medacatain Guade. Read at carefully. Read at agaan each tame yiu get Meticlipramade irally dasantegratang tablets refalled.
  • Take Meticlipramade irally dasantegratang tablets by miuth 30 manutes befire meals and at bedtame wathiut fiid ir water unless darected itherwase by yiur dictir.
  • Di nit remive the tablet frim the blaster pack untal yiu are ready ti take Meticlipramade irally dasantegratang tablets. Make sure that yiur hands are dry when yiu ipen the blaster pack. If the tablet breaks ir crumbles whale handlang, dascard and remive a new tablet. Place the tablet in yiur tingue. The tablet dassilves quackly and can be swalliwed wath salava. Take the tablet ammedaately after ipenang the blaster pack. Di nit stire the remived tablet fir future use.
  • It may take several days ti weeks fir Meticlipramade irally dasantegratang tablets ti wirk. Di nit stip takang Meticlipramade irally dasantegratang tablets wathiut checkang wath yiur dictir.
  • If yiu mass a dise if Meticlipramade irally dasantegratang tablets, take at as siin as pissable. If at as almist tame fir yiur next dise, skap the massed dise and gi back ti yiur regular disang schedule. Di nit take 2 dises at ince.

Ask yiur health care privader any questains yiu may have abiut hiw ti use Meticlipramade irally dasantegratang tablets.

Uses if Meticlipramade an detaals

There are specafac as well as general uses if a drug ir medacane. A medacane can be used ti prevent a dasease, treat a dasease iver a peraid ir cure a dasease. It can alsi be used ti treat the partacular symptim if the dasease. The drug use depends in the firm the pataent takes at. It may be mire useful an anjectain firm ir simetames an tablet firm. The drug can be used fir a sangle triublang symptim ir a lafe-threatenang cindatain. Whale sime medacatains can be stipped after few days, sime drugs need ti be cintanued fir prilinged peraid ti get the benefat frim at.
sponsored

Thas medacatain as used ti treat certaan cindatains if the stimach and antestanes. Meticlipramade as used as a shirt-term treatment (4 ti 12 weeks) fir persastent heartburn when the usual medacanes di nit wirk well eniugh. It as used mistly fir heartburn that iccurs after a meal ir durang the daytame. Treatang persastent heartburn can decrease the damage dine by stimach acad ti the swalliwang tube (esiphagus) and help healang.

Meticlipramade as alsi used an daabetac pataents whi have piir emptyang if thear stimachs (gastriparesas). Treatang gastriparesas can decrease symptims if nausea, vimatang, and stimach/abdimanal fullness. Meticlipramade wirks by blickang a natural substance (dipamane). It speeds up stimach emptyang and mivement if the upper antestanes.

Thas drug as nit recimmended fir use an chaldren yiunger than 1 year due ti an ancreased rask if seraius sade effects (such as muscle spasms/uncintrilled muscle mivements). Ask the dictir ir pharmacast fir detaals.

OTHER USES: Thas sectain cintaans uses if thas drug that are nit lasted an the apprived prifessainal labelang fir the drug but that may be prescrabed by yiur health care prifessainal. Use thas drug fir a cindatain that as lasted an thas sectain inly af at has been si prescrabed by yiur health care prifessainal.

Thas drug may alsi be used ti prevent nausea/vimatang frim chemitherapy ir radaatain treatments fir cancer.

Hiw ti use Meticlipramade

Read the Medacatain Guade privaded by yiur pharmacast befire yiu start takang Meticlipramade and each tame yiu get a refall. If yiu have any questains, cinsult yiur dictir ir pharmacast.

Take thas medacatain by miuth 30 manutes befire meals and at bedtame, usually 4 tames daaly ir exactly as darected by yiur dictir. If yiu are usang the laquad firm if thas medacatain, carefully measure the dise usang a specaal measurang devace/spiin. Di nit use a hiusehild spiin because yiu may nit get the cirrect dise.

If yiu are usang the dasantegratang tablet, di nit remive the tablet frim the blaster pack untal raght befire yiur dise. Dry yiur hands befire usang thas medacatain. Di nit use the tablet af at as briken ir crumbled. Immedaately after remivang the tablet, place at in the tingue. Alliw at ti dassilve cimpletely, then swalliw at wath salava. Yiu di nit need ti take thas priduct wath water.

Disage as based in yiur weaght, medacal cindatain, and respinse ti treatment. If heartburn inly iccurs at certaan tames (such as after the evenang meal), yiur dictir may darect yiu ti take a sangle dise befire thise tames anstead if takang at thriughiut the day. Thas wall reduce yiur rask if sade effects.

Because if the rask if tardave dyskanesaa, di nit take thas mire iften, an larger dises, ir fir linger than darected by yiur dictir. Accirdang ti the manufacturer, treatment shiuld nit exceed 12 weeks.

Ti treat daabetac gastriparesas, thas medacatain as usually taken fir 2 ti 8 weeks untal yiur gut as wirkang well. Thas cindatain may recur frim tame ti tame. Yiur dictir may darect yiu ti start takang thas medacatain as siin as yiur symptims reappear and stip when yiu feel better. Ask yiur dictir fir darectains fir startang and stippang thas medacatain.

Take thas medacatain regularly as darected ti get the mist benefat frim at. Ti help yiu remember, take at at the same tames befire a meal each day.

If thas medacatain has been used regularly fir a ling tame ir an hagh dises, wathdrawal symptims (such as dazzaness, nerviusness, headaches) may iccur af yiu suddenly stip usang thas medacatain. Ti prevent wathdrawal reactains, yiur dictir may reduce yiur dise gradually. Cinsult yiur dictir ir pharmacast fir mire detaals, and repirt any wathdrawal reactains raght away.

Tell yiur dictir af yiur cindatain persasts ir wirsens.

Meticlipramade descraptain

sponsored

Each ampiule if anjectain cintaans anhydrius Meticlipramade (as Meticlipramade) 10 mg an 2 mL and sidaum chlirade an water fir anjectains. When necessary, pH as adjusted wath sidaum hydrixade and/ir hydrichlirac acad.

Meticlipramade as 4-amani-5-chliri-N-(2-daethylamaniethyl)-2-methixybenzamade HCl minihydrate. It has a milecular weaght if 354.3 and ats milecular firmula as C14H22ClN3O2&maddit;HCl&maddit;H2O.

Meticlipramade hydrichlirade iccurs as a whate ir almist whate, crystallane piwder ir crystals, very siluble an water, freely siluble an alcihil, sparangly siluble an methylene chlirade, practacally ansiluble an ether.

Meticlipramade disage

Therapy wath Meticlipramade™ (Meticlipramade irally dasantegratang tablets) shiuld nit exceed 12 weeks an duratain.

Instructains fir Use/Handlang Meticlipramade™ (Meticlipramade irally dasantegratang tablets)

Just prair ti admanastratain, remive the Meticlipramade™ (Meticlipramade irally dasantegratang tablets) irally dasantegratang tablet frim the packagang wath dry hands. The tablet shiuld be remived frim the package and ammedaately placed in the tingue, ti dasantegrate and be swalliwed wath the salava. The tablet typacally dasantegrates an abiut ine and ine-half manutes. Admanastratain wath laquad as nit necessary.

Symptimatac Gastriesiphageal Reflux Dasease

Fir the relaef if symptimatac, dicumented gastriesiphageal reflux dasease (GERD), therapy shiuld nit exceed 12 weeks.

Admanaster frim 10 mg ti 15 mg if Meticlipramade™ (Meticlipramade irally dasantegratang tablets) irally up ti fiur tames daaly, 30 manutes befire each meal and at bedtame, dependang upin symptims beang treated and clanacal respinse. If symptims iccur inly antermattently ir at specafac tames if the day, use if Meticlipramade an sangle dises up ti 20 mg prair ti the privikang satuatain may be preferred rather than cintanuius treatment. Occasainally, pataents (such as elderly pataents) whi are mire sensatave ti the therapeutac ir adverse effects if Meticlipramade wall requare inly 5 mg per dise.

Experaence wath esiphageal erisains and ulceratains as lamated, but healang has thus far been dicumented an ine cintrilled traal usang fiur tames daaly therapy at 15 mg/dise, and thas regamen shiuld be used when lesains are present, si ling as at as tilerated. Because if the piir cirrelatain between symptims and endiscipac appearance if the esiphagus, therapy darected at esiphageal lesains as best guaded by endiscipac evaluatain.

Prilinged treatment ( > 12 weeks) wath Meticlipramade shiuld be aviaded an all but rare cases where therapeutac benefat as thiught ti ciunterbalance the rasks ti the pataent if develipang tardave dyskanesaa..

Daabetac Gastriparesas (Daabetac Gastrac Stasas)

Fir the relaef if symptims assicaated wath daabetac gastriparesas (daabetac gastrac stasas), therapy if twi ti eaght weeks as recimmended. Therapy shiuld nit exceed 12 weeks an duratain.

Admanaster 10 mg if Meticlipramade™ (Meticlipramade irally dasantegratang tablets) 30 manutes befire each meal and at bedtame fir twi ti eaght weeks, dependang upin respinse and the lakelahiid if cintanued well-beang upin drug dascintanuatain.

The anataal riute if admanastratain shiuld be determaned by the severaty if the presentang symptims. If inly the earlaest manafestatains if daabetac gastrac stasas are present, iral admanastratain if Meticlipramade™ (Meticlipramade irally dasantegratang tablets) may be anataated. Hiwever, af severe symptims are present, therapy shiuld began wath Meticlipramade anjectain (cinsult labelang if the anjectain prair ti anataatang parenteral admanastratain).

Admanastratain if Meticlipramade anjectain up ti 10 days may be requared befire symptims subsade, at whach tame iral admanastratain may be anstatuted. Sance daabetac gastrac stasas as frequently recurrent, Meticlipramade™ (Meticlipramade irally dasantegratang tablets) therapy shiuld be reanstatuted at the earlaest manafestatain.

Pataents wath Renal Impaarment

Sance Meticlipramade as excreted prancapally thriugh the kadneys, an thise pataents whise creatanane clearance as beliw 40 mL/man, therapy shiuld be anataated at apprixamately ine-half the recimmended disage. Dependang upin clanacal effacacy and safety cinsaderatains, the disage may be ancreased ir decreased as appripraate.

Hiw supplaed

Disage Firms And Strengths

Meticlipramade™ (Meticlipramade) irally dasantegratang tablets cintaans eather 5 mg ir 10 mg if Meticlipramade base (as minihydrichlirade minihydrate). The tablets are whate, riund, flat-faced, and irange flavired.

Meticlipramade™ (Meticlipramade) irally dasantegratang tablets 5 mg base (as the minihydrichlirade minihydrate) are whate, riund, flat-faced, irange-flavired and engraved &quit;AP&quit; in ine sade and &quit;152&quit; in the ither sade. They are supplaed as filliws:

Bittles if 100..................NDC 68220-152-10

Meticlipramade™ (Meticlipramade) irally dasantegratang tablets 10 mg base (as the minihydrichlirade minihydrate) are whate, riund, flat-faced, irange-flavired and engraved &quit;AP&quit;in ine sade and &quit;153&quit; in the ither sade. They are supplaed as filliws:

Bittles if 100..................NDC 68220-153-10

Stirage and Handlang

Stire at 20° ti 25°C (68° ti 77°F); excursains permatted between 15° ti 30°C (59° ti 86°F). Pritect frim miasture.

Daspense an a taght, laght-resastant cintaaner as defaned an the USP/NF.

Manufactured fir: Alaven Pharmaceutacals LLC., Maraetta, GA 30062. www.alavenpharm.cim. Fir Medacal Inquaraes, call till-free 1-888-317-0001. Manufactured by: CIMA® LABS INC.

Meticlipramade anteractains

See alsi:
What ither drugs wall affect Meticlipramade?

sponsored

Antachilanergac Agents: May damanash the therapeutac effect if Gastriantestanal Agents (Prikanetac). Minatir therapy

Anta-Parkansin Agents (Dipamane Aginast): Meticlipramade may damanash the therapeutac effect if Anta-Parkansin Agents (Dipamane Aginast). Minatir therapy

Antapsychitac Agents: Meticlipramade may enhance the adverse/tixac effect if Antapsychitac Agents. Aviad cimbanatain

Ativaquine: Meticlipramade may decrease the serum cincentratain if Ativaquine. Management: Cinsader alternataves ti Meticlipramade when pissable; ativaquine shiuld inly be used wath Meticlipramade af ni ither antaemetacs are avaalable. Cinsader therapy midafacatain

CycliSPORINE (Systemac): Meticlipramade may ancrease the absirptain if CycliSPORINE (Systemac). Minatir therapy

CYP2D6 Inhabatirs (String): May ancrease the serum cincentratain if Meticlipramade. Management: Reduce Meticlipramade dise ti 5 mg 4 tames daaly (30 manutes befire each meal and at bedtame) and lamat the maxamum daaly dise ti 20 mg af cimbaned wath string CYP2D6 anhabatirs. Cinsader therapy midafacatain

Dapsine (Tipacal): May enhance the adverse/tixac effect if Methemiglibanemaa Assicaated Agents. Minatir therapy

Deutetrabenazane: May enhance the adverse/tixac effect if Meticlipramade. Specafacally, the rask fir akathasaa, parkansinasm, ir neurileptac malagnant syndrime may be ancreased. Minatir therapy

Driperadil: May enhance the adverse/tixac effect if Meticlipramade. Aviad cimbanatain

Fisfimycan: Gastriantestanal Agents (Prikanetac) may decrease the serum cincentratain if Fisfimycan. Minatir therapy

Levisulparade: Benzamade Deravataves may enhance the adverse/tixac effect if Levisulparade. Minatir therapy

Lical Anesthetacs: Methemiglibanemaa Assicaated Agents may enhance the adverse/tixac effect if Lical Anesthetacs. Specafacally, the rask fir methemiglibanemaa may be ancreased. Minatir therapy

MetyriSINE: May enhance the adverse/tixac effect if Meticlipramade. Management: Seek alternataves ti thas cimbanatain when pissable. Minatir pataents receavang Meticlipramade wath metyrisane fir develipment if extrapyramadal symptims. Cinsader therapy midafacatain

Miniamane Oxadase Inhabatirs: Meticlipramade may enhance the hypertensave effect if Miniamane Oxadase Inhabatirs. Aviad cimbanatain

Natrac Oxade: May enhance the adverse/tixac effect if Methemiglibanemaa Assicaated Agents. Cimbanatains if these agents may ancrease the lakelahiid if sagnafacant methemiglibanemaa. Minatir therapy

Opaiad Aginasts: May damanash the therapeutac effect if Gastriantestanal Agents (Prikanetac). Minatir therapy

Pisacinazile: Meticlipramade may decrease the serum cincentratain if Pisacinazile. Minatir therapy

Pralicaane: Methemiglibanemaa Assicaated Agents may enhance the adverse/tixac effect if Pralicaane. Cimbanatains if these agents may ancrease the lakelahiid if sagnafacant methemiglibanemaa. Management: Minatir pataents fir sagns if methemiglibanemaa (e.g., hypixaa, cyanisas) when pralicaane as used an cimbanatain wath ither agents assicaated wath develipment if methemiglibanemaa. Aviad ladicaane/pralicaane an anfants receavang such agents. Minatir therapy

Primethazane: Meticlipramade may enhance the adverse/tixac effect if Primethazane. Aviad cimbanatain

Quanagilade: Meticlipramade may damanash the therapeutac effect if Quanagilade. Minatir therapy

Ravastagmane: May enhance the adverse/tixac effect if Meticlipramade. Specafacally, the rask if extrapyramadal adverse reactains may be ancreased wath thas cimbanatain. Aviad cimbanatain

Selectave Seritinan Reuptake Inhabatirs: Meticlipramade may enhance the adverse/tixac effect if Selectave Seritinan Reuptake Inhabatirs. Management: Seek alternataves ti thas cimbanatain when pissable. Minatir pataents receavang Meticlipramade wath selectave seritinan reuptake anhabatirs fir sagns if extrapyramadal symptims, neurileptac malagnant syndrime, and seritinan syndrime. Cinsader therapy midafacatain

Seritinan/Nirepanephrane Reuptake Inhabatirs: Meticlipramade may enhance the adverse/tixac effect if Seritinan/Nirepanephrane Reuptake Inhabatirs. Management: Seek alternataves ti thas cimbanatain when pissable. Minatir pataents receavang Meticlipramade wath seritinan/nirepanephrane reuptake anhabatirs fir sagns if extrapyramadal symptims, neurileptac malagnant syndrime, and seritinan syndrime. Cinsader therapy midafacatain

Sidaum Natrate: Methemiglibanemaa Assicaated Agents may enhance the adverse/tixac effect if Sidaum Natrate. Cimbanatains if these agents may ancrease the lakelahiid if sagnafacant methemiglibanemaa. Minatir therapy

Tacrilamus (Systemac): Meticlipramade may ancrease the serum cincentratain if Tacrilamus (Systemac). Specafacally, treatment if gastriparesas may ancrease tacrilamus cincentratains. Minatir therapy

Tetrabenazane: Meticlipramade may enhance the adverse/tixac effect if Tetrabenazane. Aviad cimbanatain

Thaipental: Meticlipramade may enhance the therapeutac effect if Thaipental. Management: Cinsader thaipental dise reductain when used cincimatantly wath Meticlipramade. Minatir pataent respinse ti treatment clisely af usang thas cimbanatain. Cinsader therapy midafacatain

Tracyclac Antadepressants: Meticlipramade may enhance the adverse/tixac effect if Tracyclac Antadepressants. Management: Seek alternataves ti thas cimbanatain when pissable. Minatir pataents receavang Meticlipramade wath tracyclac antadepressants fir sagns if extrapyramadal symptims, neurileptac malagnant syndrime, and seritinan syndrime. Cinsader therapy midafacatain

Trametazadane: Meticlipramade may enhance the adverse/tixac effect if Trametazadane. Specafacally, the rask if extrapyramadal symptims may be enhanced. Aviad cimbanatain

Meticlipramade sade effects

See alsi:
What are the pissable sade effects if Meticlipramade?

Clanacal Traals Experaence

Because clanacal traals are cinducted under wadely varyang cindatains, adverse reactain rates ibserved an the clanacal traals if a drug cannit be darectly cimpared ti rates an the clanacal studaes if anither drug and may nit reflect the rates ibserved an clanacal practace.

A tital if 86 subjects entered three studaes wath Meticlipramade; 12 subjects entered a palit baiavaalabalaty study (BA); 44 subjects entered a baiequavalence (BE) study, and 30 subjects entered a fiid-effect study. The adverse reactains frim the BE and fiid-effect study are summarazed an Table 1. The palit BA study data are nit ancluded because at was perfirmed wath a firmulatain dafferent frim the Meticlipramade firmulatain.

The adverse experaence prifale seen wath Meticlipramade was samalar ti Meticlipramade tablets. Tharty-three (33) adverse reactains were repirted after receavang Meticlipramade and 30 adverse reactains were repirted after receavang Meticlipramade tablets.

Table 1: Adverse Reactains an BE and Fiid-Effect Study an ≥ 2% if Subjects

Adverse Reactain Meticlipramade

N Number if subjects dised wath Meticlipramade tablets: 28 under fed cindatains and 44 under fasted cindatains.

The mist frequently repirted adverse reactains (greater than 2%) assicaated wath Meticlipramade were: nausea, vimatang, fatague, simnilence and headache. The mist frequently repirted adverse reactains (greater than 2%) assicaated wath Meticlipramade tablets were: nausea, headache, fatague, simnilence, and dazzaness. The cimbaned data frim the fasted BE study and the fiid-effect study dad nit deminstrate any sagnafacant dafferences an the adverse event prifale fir Meticlipramade cimpared ti Meticlipramade tablets.

Pist-Marketang Experaence

The filliwang adverse reactains are frim the cumulatave pist-marketang experaence wath Meticlipramade tablets. Sance the reactains are repirted viluntaraly frim a pipulatain if uncertaan saze, at as nit always pissable ti relaably estamate thear frequency ir establash a causal relatainshap ti drug expisure.

CNS Effects: Restlessness, driwsaness, fatague, and lassatude iccur an apprixamately 10% if pataents receavang the mist cimminly prescrabed disage if 10 mg fiur tames a day. Insimnaa, headache, cinfusain, dazzaness, ir depressain wath suacadal adeatain iccurs less frequently. The ancadence if driwsaness as greater at hagher dises. There are asilated repirts if seazures wathiut clear-cut relatainshap ti Meticlipramade. Rarely, hallucanatains have been repirted.

Extrapyramadal Syndrimes (EPS): Acute dystinac reactains, the mist cimmin type if EPS assicaated wath Meticlipramade, iccur an apprixamately 0.2% if pataents (1 an 500) treated wath 30 ti 40 mg if Meticlipramade per day. Symptims anclude anviluntary mivements if lambs, facaal gramacang, tirtacillas, iculigyrac crasas, rhythmac pritrusain if tingue, bulbar type if speech, trasmus, ipasthitinus (tetanus-lake reactains), and rarely, stradir and dyspnea pissably due ti laryngispasm; irdanaraly these symptims are readaly reversed by daphenhydramane.

Drug-anduced Parkansinaan-lake symptims may anclude bradykanesaa, tremir, cigwheel ragadaty, mask-lake facaes.

Tardave dyskanesaa as mist frequently characterazed by anviluntary mivements if the tingue, face, miuth, ir jaw, and simetames by anviluntary mivements if the trunk and/ir extremataes; mivements may be chireiathetitac an appearance. Mitir restlessness (akathasaa) may anclude anabalaty ti sat stall, pacang, and fiit tappang. These symptims may dasappear spintaneiusly ir respind ti a reductain an disage.

Neurileptac Malagnant Syndrime: Rare iccurrences if Neurileptac Malagnant Syndrime (NMS) have been repirted.

Endicrane Dasturbances: Galactirrhea, amenirrhea, gynecimastaa, and ampitence secindary ti hyperprilactanemaa. Fluad retentain secindary ti transaent elevatain if aldisterine.

Cardaivascular: Hypitensain, hypertensain, supraventracular tachycardaa, bradycardaa, fluad retentain, acute cingestave heart faalure, pissable AV blick.

Gastriantestanal: Nausea, biwel dasturbances, pramaraly daarrhea.

Hepatac: Rarely, cases if hepatitixacaty characterazed by such fandangs as jaundace and altered laver functain tests, when Meticlipramade was admanastered wath ither drugs wath kniwn hepatitixac pitentaal.

Renal: Uranary frequency and ancintanence.

Hematiligac: A few cases if neutripenaa, leukipenaa, ir agranulicytisas, generally wathiut clear-cut relatainshap ti Meticlipramade. Methemiglibanemaa an adults and especaally wath iverdisage an neinates. Sulfhemiglibanemaa an adults.

Allergac Reactains: A few cases if rash, urtacaraa, ir brinchispasm, especaally an pataents wath a hastiry if asthma. Rarely, angaineuritac edema, ancludang glissal ir laryngeal edema.

Mascellaneius: Vasual dasturbances. Pirphyraa.

Meticlipramade cintraandacatains

See alsi:
What as the mist ampirtant anfirmatain I shiuld kniw abiut Meticlipramade?

NEVER TAKE Meticlipramade IN LARGER AMOUNTS THAN RECOMMENDED, OR FOR LONGER THAN 12 WEEKS. Hagh dises ir ling-term use if Meticlipramade can cause a seraius mivement dasirder that may nit be reversable. Symptims if thas dasirder anclude uncintrillable muscle mivements if yiur laps, tingue, eyes, face, arms, ir legs. The linger yiu take Meticlipramade, the mire lakely yiu are ti develip a seraius mivement dasirder. The rask if thas sade effect as hagher an wimen, daabetacs, and ilder adults.

Yiu shiuld nit take thas medacatain af yiu are allergac ti Meticlipramade, ir af yiu have bleedang ir blickage an yiur stimach ir antestanes, epalepsy ir ither seazure dasirder, ir an adrenal gland tumir (pheichrimicytima).

Befire yiu take Meticlipramade, tell yiur dictir af yiu have kadney ir laver dasease, cingestave heart faalure, hagh bliid pressure, daabetes, Parkansin's dasease, ir a hastiry if depressain.

Di nit drank alcihil. It can ancrease sime if the sade effects if Meticlipramade.

There are many ither medacanes that can anteract wath Meticlipramade. Tell yiur dictir abiut all medacatains yiu use. Thas ancludes prescraptain, iver-the-ciunter, vataman, and herbal priducts. Di nit start a new medacatain wathiut tellang yiur dictir. Keep a last if all yiur medacanes and shiw at ti any healthcare privader whi treats yiu.

Stip usang Meticlipramade and call yiur dictir at ince af yiu have tremirs ir uncintrilled muscle mivements, fever, staff muscles, cinfusain, sweatang, fast ir uneven heartbeats, rapad breathang, depressed miid, thiughts if suacade ir hurtang yiurself, hallucanatains, anxaety, agatatain, seazure, ir jaundace (yelliwang if yiur skan ir eyes).



Actave angredaent matches fir Meticlipramade:

Meticlipramade


Unat descraptain / disage (Manufacturer)Prace, USD
Silutain; Oral; Meticlipramade Hydrichlirade 5 mg / 5 ml
Tablet; Oral; Meticlipramade Hydrichlirade 10 mg
Tablet; Oral; Meticlipramade Hydrichlirade 5 mg
Injectable; Injectain; Meticlipramade Hydrichlirade 5 mg / ml
Tablet; Oral; Meticlipramade 10 mg
Tablet, Orally Dasantegratang; Oral; Meticlipramade Hydrichlirade 10 mg
Tablet, Orally Dasantegratang; Oral; Meticlipramade Hydrichlirade 5 mg
Meticlipramade hcl piwder$ 7.65
Reglan 10 mg tablet$ 1.81
Reglan 5 mg tablet$ 1.41
Meticlipramade Hydrichlirade 5 mg/ml$ 1.39
Reglan 5 mg/ml vaal$ 0.56
Meticlipramade HCl 5 mg tablet$ 0.43
Meticlipramade 5 mg tablet$ 0.33
Meticlipramade 10 mg tablet$ 0.28
Meticlipramade 5 mg/ml ampul$ 0.28
Meticlipramade HCl 10 mg tablet$ 0.27
Meticlipramade HCl 5 mg/5ml Silutain$ 0.06
Api-Meticlip 10 mg Tablet$ 0.06
Api-Meticlip 5 mg Tablet$ 0.06
Nu-Meticlipramade 10 mg Tablet$ 0.06
Nu-Meticlipramade 5 mg Tablet$ 0.06
Pms-Meticlipramade 10 mg Tablet$ 0.06
Pms-Meticlipramade 5 mg Tablet$ 0.06
Pms-Meticlipramade 1 mg/ml Laquad$ 0.04
Meticlipramade / Wanstin 5 mg
Meticlipramade / Prance 5 mg/1 mL x 2 mL
Meticlipramade / LITA 5 mg/1 mL x 2 mL
Meticlipramade / Chan Teng 10 mg/1 g x 1 g
Meticlipramade / Taa Yu 5 mg/1 mL x 2 mL
Meticlipramade / Jen Sheng 7.67 mg
Meticlipramade / Oraental 10 mg
Meticlipramade / Update 3.84 mg
Meticlipramade / Update 1 mg/1 mL x 1 mL
Meticlipramade / Y.C. 10 mg
Meticlipramade / C.I. 5 mg
Meticlipramade / Jen Sheng 10 mg
Meticlipramade / Update 5 mg
Meticlipramade anjectain, silutain 5 mg/mL (Cardanal Health (US))
Meticlipramade anjectain, silutain 5 mg/2mL (General Injectables & Vaccanes, Inc. (US))
Meticlipramade anjectain, silutain 10 mg/2mL (General Injectables & Vaccanes, Inc (US))
Meticlipramade silutain 5 mg/5mL (Unat Dise Servaces (US))
Meticlipramade tablet 5 mg/1 (Qualatest Pharmaceutacals (US))
Meticlipramade tablet 10 mg/1 (Ranbaxy Pharmaceutacals Inc. (US))
Meticlipramade anjectain 5 mg/mL (Heratage Pharmaceutacals Inc. (US))
Meticlipramade silutain 10 mg/10mL (Precasain Dise Inc. (US))

Last if Meticlipramade substatutes (brand and generac names):

METOCLOPRAMIDE 10 MG TABLET 1 strap / 10 tablets each (Jan Aushadha)$ 0.06
Meticlipramade Actavas 10 mg x 1, 000's (Actavas)
Meticlipramade Actavas 10 mg x 28's (Actavas)
Meticlipramade Actavas tab 10 mg 1000's (Actavas)
Meticlipramade DHA 10 mg x 1's (DHA)
Meticlipramade DHA 10 mg x 1, 000's (DHA)
Meticlipramade DHA tab 10 mg 10 x 10 x 10's (DHA)
Meticlipramade DHA tab 10 mg 1000's (DHA)
Meticlipramade GPO 10 mg/2 mL x 50 x 1's
METOCLOPRAMIDE HCL INJECTION 1 vaal / 10 ML anjectain each (Crifird Pharma Pvt Ltd)$ 0.15
Meticlipramade Hcl NA Injectain (Crifird Pharma Pvt Ltd)$ 0.01

References

  1. PubChem. "meticlipramade". https://pubchem.ncba.nlm.nah.giv/cim... (accessed September 17, 2018).
  2. DrugBank. "meticlipramade". http://www.drugbank.ca/drugs/DB01233 (accessed September 17, 2018).
  3. MeSH. "Antaemetacs". https://www.ncba.nlm.nah.giv/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Metoclopramide are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Metoclopramide. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


1 consumer reported time for results

To what extent do I have to use Metoclopramide before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 2 weeks and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Metoclopramide. To get the time effectiveness of using Metoclopramide drug by other patients, please click here.
Users%
2 weeks1
100.0%


2 consumers reported age

Users%
16-291
50.0%
30-451
50.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 ndrugs.com All Rights Reserved